GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the gastrointestinal tract in response to food intake. It enhances pancreatic islet β-cell proliferation and glucose-dependent insulin secretion, and lowers blood glucose and food intake in patients with type 2 diabetes mellitus (T2DM). A long-acting GLP-1 receptor (GLP-1R) agonist, exendin-4 (Ex-4), is the first of this new class of antihyperglycemia drugs approved to treat T2DM. GLP-1Rs are coupled to the cAMP second messenger pathway and, along with pancreatic cells, are expressed within the nervous system of rodents and humans, where receptor activation elicits neurotrophic actions. We detected GLP-1R mRNA expression in both cultured embryonic primary cerebral cortical and ventral mesencephalic (dopaminergic) neurons. These cells are vulnerable to hypoxia- and 6-hydroxydopamine–induced cell death, respectively. We found that GLP-1 and Ex-4 conferred protection in these cells, but not in cells from Glp1r knockout (-/-) mice. Administration of Ex-4 reduced brain damage and improved functional outcome in a transient middle cerebral artery occlusion stroke model. Ex-4 treatment also protected dopaminergic neurons against degeneration, preserved dopamine levels, and improved motor function in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease (PD). Our findings demonstrate that Ex-4 can protect neurons against metabolic and oxidative insults, and they provide preclinical support for the therapeutic potential for Ex-4 in the treatment of stroke and PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, GLP-1RAs have demonstrated considerable therapeutic promise in animal models of both PD and AD.427–429”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to its effects on metabolic regulation, GLP-1, when synthesized within the brain, exhibits neuroprotective properties.397,427,431”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [427]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“There is increasing evidence from animal studies and clinical trials to suggest that GLP-1 receptor agonists could be beneficial in the treatment of PD, and one study using a prebiotic supplement that enhanced SCFA levels showed an increase GLP-1 levels in mouse models [141–144].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 10×
“These and other actions are mediated through the G protein-coupled GLP-1R, and Ex-4 has demonstrated therapeutic value in T2DM (7).”
BackgroundMethodInfluentialDiabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“GLP-1R mRNA occurs widely throughout the brains of rodents (9) and humans (6,7,10), and both GLP-1 and Ex-4 can readily enter the brain (11) to modify feeding and satiety (12).”
BackgroundJavitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263 · cited 2×
“Administration of MPTP in mice induces a consistent dopaminergic cell loss that parallels many aspects of PD (16,20).”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 3×
“Although T2DM now occurs more often in the young, the incidence rises dramatically with age, along with that of many of other conditions, including acute and chronic neurologic disorders, exemplified by stroke (2), Parkinson’s disease (PD) and Alzheimer’s disease (AD) (3,4), which, like T2DM, were once considered rela…”
BackgroundD'Mello, S. R., Galli, C., Ciotti, T., & Calissano, P. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.23.10989 · Cited by 892 · cited 1×
“cAMPmediated pathways are central to the antiapoptotic actions of GLP-1 in -cells (6–8), and the neuroprotective effects of cAMPelevating agents are seen in many neuronal cells, including sensory (24), dopaminergic (25), septal cholinergic (26), cerebellar granule (27,28), and spinal cord motor neurons (29).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“These neurotrophic/protective actions are in accordance with previous findings establishing that GLP-1R stimulation protects hippocampal neurons from amyloid- peptide–, Fe2 -, and glutamate-induced toxicity (15,32,33).”
BackgroundResultInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Mattson, M. P. (2007) · Aging Cell · doi:10.1111/j.1474-9726.2007.00275.x · Cited by 751 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
BackgroundSelf-citationCell death in the nervous system
Bredesen, D. E., Rao, R. V., & Mehlen, P. (2006) · Nature · doi:10.1038/nature05293 · Cited by 636 · cited 2×
“Evidence for classic apoptosis in both conditions includes elevated levels of the apoptotic stress-activated protein kinases, caspase-3 (19–21) and of proapoptotic genes and proteins (19,21,22), as was evident in our cell culture studies.”
Background
Research works printed but not linked: 2
- R Sicree, J Shaw, P Zimmet Diabetes Atlas, ed D Gan (International Diabetes Federation, 3rd Ed, Brussels), pp. 15–103 (2006).
- 10.1210/endo.140.3.6550 · doi:10.1210/endo.140.3.6550 · Paper page
Cited by
Items 101–200 of 629
The Relevance of Insulin Action in the Dopaminergic System
Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F. C., Miele, C., Beguinot, F., Formisano, P., & Oriente, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00868 · Cited by 111
Therapeutic Effect of Berberine on Huntington’s Disease Transgenic Mouse Model
Jiang, W., Wei, W., Gaertig, M. A., Li, S., & Li, X.-J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134142 · Cited by 124
Girgis, F., Pace, J., Sweet, J. A., & Miller, J. P. (2016) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2016.00008 · Cited by 126
“GLP-1 was initially described based on its role in the pancreatic regulation of insulin, but receptors are also found in the CNS and changes in this pathway have been implicated in a number of neurodegenerative diseases (Li et al., 2009, 2010, 2012; Martin et al., 2009; Salcedo et al., 2012).”
BackgroundParkes, D. G., Mace, K. F., & Trautmann, M. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 108
“In rodent models, GLP-1 and exendin-4 were neuroprotective against insults that modeled stroke and Parkinson’s disease, an effect antagonized by a GLP-1 receptor antagonist and absent in cells from GLP-1 receptor KO mice [88].”
BackgroundGodinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., & Reis, F. (2015) · Journal of Diabetes Research · doi:10.1155/2015/806979 · Cited by 109
Hyun Lee, C., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118
“In addition, GLP-1 and EX-4 have been known to have neurotrophic and neuroprotective properties in many in vitro and in vivo studies using models of stroke and neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases (Perry et al., 2002, 2003; During et al., 2003; Bertilsson et al., 2008; Harkavyi et a…”
BackgroundResultInfluentialNeuroprotective Effects of Liraglutide for Stroke Model of Rats
Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121513 · Cited by 120
“disease mouse model, induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which might also suggest that therapeutic effects of exenatide were strongly related to anti-oxidative effects [8].”
BackgroundFeng, P., Zhang, X., Li, D., Ji, C., Yuan, Z., Wang, R., Xue, G., Li, G., & Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.012 · Cited by 120
“Furthermore, previous studies found that GLP-1 receptor agonists also have neuroprotective effects in animal models of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Li et al., 2009; Liu et al., 2015a; Zhang et al., 2015).”
Parthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.012 · Cited by 119
“, 2011), and GLP-1 analogues such as liraglutide have shown several neuroprotective effects in mouse models of stroke, Alzheimer’s or Parkinson’s disease (Harkavyi et al., 2008; Li et al., 2009; McClean et al., 2011), these drugs show great promise as a potential treatment of such neurodegenerative conditions.”
BackgroundNeuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease
Chen, Y., Zhang, Y., Li, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.029 · Cited by 119
“MPTP is a widely used chemical to induce a Parkinson-like state in animals to test new drug candidates (Kim et al., 2009; Kopin and Markey, 1988; Li et al., 2009; Nakamura and Vincent, 1986).”
BackgroundBeneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 112
“These data also are consistent with previous reports (14,16,18,19) that revealed the plausible effects of GLP-1 or GLP-1R agonists on central and peripheral nerve disorders.”
ResultEmerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
Gouda, N. A., Elkamhawy, A., & Cho, J. (2022) · Biomedicines · doi:10.3390/biomedicines10020371 · Cited by 119
Tong, B., Ba, Y., Li, Z., Yang, C., Su, K., Qi, H., Zhang, D., Liu, X., Wu, Y., Chen, Y., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106505 · Cited by 117
Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer’s Disease: Review and Meta-Analysis
Athanasaki, A., Melanis, K., Tsantzali, I., Stefanou, M., Ntymenou, S., Paraskevas, S. G., Κalamatianos, T., Boutati, E. I., Lambadiari, V., Voumvourakis, K. I., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10040778 · Cited by 118
“Thus, mice treated with exendin-4 showed an increase in dopamine levels and in the density of neurons in the substantia nigra [107,108].”
BackgroundYuan, Z., Li, D., Feng, P., Xue, G., Ji, C., Li, G., & Hölscher, C. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.06.029 · Cited by 116
“GLP-1 receptor agonists also have neuroprotective effects in animal models of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Li et al., 2009; Liu et al., 2015a; Zhang et al., 2015).”
BackgroundInsulin resistance and exendin-4 treatment for multiple system atrophy
Bassil, F., Canron, M.-H., Vital, A., Bezard, E., Li, Y., Greig, N. H., Gulyani, S., Kapogiannis, D., Fernagut, P.-O., & Meissner, W. G. (2017) · Brain · doi:10.1093/brain/awx044 · Cited by 107
Self-citationMcIntyre, R. S., Powell, A. M., Kaidanovich-Beilin, O., Soczynska, J. K., Alsuwaidan, M., Woldeyohannes, H. O., Kim, A. S., & Gallaugher, L. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.021 · Cited by 110
Gut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Lin, S., Wang, Z., Lam, K.-L., Zeng, S., Tan, B. K., & Hu, J. (2019) · Food & Nutrition Research · doi:10.29219/fnr.v63.1518 · Cited by 95
“Polyphenols modulate glucagon-like peptide-1 secretion Glucagon-like peptide-1 (GLP-1) is an endogenous insulinotropic peptide secreted from the intestine L cells in response to food intake (107).”
BackgroundKim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Sebastião, I., Candeias, E., Santos, M. S., de Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00110 · Cited by 92
“Additionally, Exe-4 decreases food intake (128) and, together with metformin and/or SUs, lowers HbA1C levels by 0.”
BackgroundThe Gut Hormones in Appetite Regulation
Suzuki, K., Jayasena, C. N., & Bloom, S. R. (2011) · Journal of Obesity · doi:10.1155/2011/528401 · Cited by 108
“cerebrovascular stroke [85], and peripheral neuropathy [88].”
Li, Y., Bader, M., Tamargo, I., Rubovitch, V., Tweedie, D., Pick, C. G., & Greig, N. H. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13169 · Cited by 103
“Parallel GLP-1mediated improvements have been described in rodent models of PD, amyotrophic lateral sclerosis and stroke (Bertilsson et al. 2008; Li et al. 2009; Li et al., 2012).”
BackgroundSelf-citationOu, S.-M., Shih, C.-J., Chao, P.-W., Chu, H., Kuo, S.-C., Lee, Y.-J., Wang, S.-J., Yang, C.-Y., Lin, C.-C., Chen, T.-J., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m15-0308 · Cited by 101
Ji, C., Xue, G., Cao, L., Feng, P., Li, D., Li, L., Li, G., & Hölscher, C. (2015) · Brain Research · doi:10.1016/j.brainres.2015.09.035 · Cited by 105
“10 previous studies showed good protection of MPTP treated mice using the GLP-1 agonist exendin-4 (Kim et al., 2009; Li et al., 2009).”
BackgroundInfluentialIncretin hormones regulate microglia oxidative stress, survival and expression of trophic factors
Spielman, L. J., Gibson, D. L., & Klegeris, A. (2017) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2017.03.004 · Cited by 105
Parkinson’s disease and diabetes mellitus: common mechanisms and treatment repurposing
Labandeira, C. M., Bau, A. F., Ron, D. A., Álvarez, E., Alba, P. V., Garma, J. L., & Rodriguez-Perez, A. I. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.332122 · Cited by 104
“These effects are mediated via GLP1R, and it has been demonstrated that GLP1R knockout animals have no benefits with treatment (Li et al., 2009).”
BackgroundYang, X., Feng, P., Zhang, X., Li, D., Wang, R., Ji, C., Li, G., & Hölscher, C. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107748 · Cited by 103
The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration
Hinkle, J. T., Dawson, V. L., & Dawson, T. M. (2019) · Movement Disorders · doi:10.1002/mds.27718 · Cited by 99
“However, these exendin-4 studies relied upon toxin-based PD models, such as intraperitoneal MPTP injection.(62) Another utilized intracerebral injection of either LPS or 6-OHDA, making it difficult to determine whether efficacy of exendin-4 administration is best attributed to intraneuronal pathways or non-cell-autono…”
BackgroundMethodThe impact of dietary energy intake on cognitive aging
Mattson (2010) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.005.2010 · Cited by 91
Self-citationHölscher, C. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140016 · Cited by 96
Santiago, J. A., & Potashkin, J. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1423573112 · Cited by 102
“Pharmacological stimulation of GLP-1 receptors with drugs used to treat diabetic patients, such as exenatide, elicits neuroprotective effects in animal models of PD (35), and its therapeutic potential has shown promise in clinical trials of PD (36–38).”
BackgroundXie, Z., Enkhjargal, B., Wu, L., Zhou, K., Sun, C., Hu, X., Gospodarev, V., Tang, J., You, C., & Zhang, J. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.040 · Cited by 96
“There is emerging evidence that besides its anti-diabetic effects, Ex-4 has the potential to carry out a neuroprotective role in central nervous system (CNS) disease (Harkavyi and Whitton, 2010; Li et al., 2009; Perry and Greig, 2005).”
BackgroundInflammation-sleep interface in brain disease: TNF, insulin, orexin
Clark, I. A., & Vissel, B. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-51 · Cited by 94
“Thus, excitation of orexin by exenatide [130] is an additional rationale for GLP-1 mimetics generating positive in vivo outcomes, beyond improving insulin resistance, in experimental models of AD [98] and PD [99], as well as T2DM.”
BackgroundCurrent disease modifying approaches to treat Parkinson’s disease
Lindholm, D., Mäkelä, J., Di Liberto, V., Mudò, G., Belluardo, N., Eriksson, O., & Saarma, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2101-1 · Cited by 99
“In addition to glitazones, T2D drugs acting through the glucagon-like peptide R1 receptor (GLP-1R) system have been shown to be neuroprotective in PD models as well as in other brain diseases [52, 53, 59].”
BackgroundShpakov, A. O., Derkach, K. V., & Berstein, L. M. (2015) · Future Science OA · doi:10.4155/fso.15.23 · Cited by 99
Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease
Athauda, D., & Foltynie, T. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.09.023 · Cited by 98
“M AN US CR IP T AC CE PT ED ACCEPTED MANUSCRIPT open-field activity, and rotarod (Li et al., 2009), while a separate study showed MPTP-treated rodents had increases in Mac1 and MMP-3 (markers of microgl ia activation) and elevated levels of proinflammatory cytokines TNFα and IL-1β (Kim et al.”
Current perspective of mitochondrial biology in Parkinson's disease
Kaidery, N. A., & Thomas, B. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.03.001 · Cited by 99
Singh, I., Wang, L., Xia, B., Liu, J., Tahiri, A., El Ouaamari, A., Wheeler, M. B., & Pang, Z. P. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00914-3 · Cited by 98
“On the other hand, although high-level of GLP-1R-expressing neurons are found in the hippocampus [46], and primary cortex [47], very few GLP-1 neuronal fiber projections were found (Fig.”
BackgroundGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Therapeutic potential of berberine against neurodegenerative diseases
Jiang, W., Li, S., & Li, X. (2015) · Science China Life Sciences · doi:10.1007/s11427-015-4829-0 · Cited by 96
Rachmany, L., Tweedie, D., Li, Y., Rubovitch, V., Holloway, H. W., Miller, J. P., Hoffer, B. J., Greig, N. H., & Pick, C. G. (2012) · AGE · doi:10.1007/s11357-012-9464-0 · Cited by 96
Self-citationWu, H.-Y., Tang, X.-Q., Mao, X.-F., & Wang, Y.-X. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1799-17.2017 · Cited by 87
“Moreover, in the mouse and rat ischemia and stroke model, treatment with exenatide also reduced brain damage after stroke and improved functional motor outcomes (Li et al., 2009).”
BackgroundSelf-citationCalsolaro, V., & Edison, P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0301-8 · Cited by 93
Darsalia, V., Hua, S., Larsson, M., Mallard, C., Nathanson, D., Nyström, T., Sjöholm, Å., Johansson, M. E., & Patrone, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103114 · Cited by 92
“With regard to stroke, intracerebral administration of Ex-4 before stroke resulted in neuroprotection [15].”
Tweedie, D., Rachmany, L., Rubovitch, V., Lehrmann, E., Zhang, Y., Becker, K. G., Perez, E., Miller, J., Hoffer, B. J., Greig, N. H., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.001 · Cited by 90
Self-citationCao, L., Li, D., Feng, P., Li, L., Xue, G.-F., Li, G., & Hölscher, C. (2016) · NeuroReport · doi:10.1097/wnr.0000000000000548 · Cited by 90
GLP-1 receptor agonists for Parkinson's disease
Mulvaney, C. A., Duarte, G. S., Handley, J., Evans, D. J., Menon, S., Wyse, R., & Emsley, H. C. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990.pub2 · Cited by 69
Liu, W. J., Jin, H. Y., Lee, K. A., Xie, S. H., Baek, H. S., & Park, T. S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01272.x · Cited by 84
“…also retarded neuron degeneration and stimulated cell proliferation by attenuating the toxicity of amyloid-b and oxidative challenge, findings that reinforce the potential value of incretins in treating Parkinson’s disease and Alzheimer’s disease (Perry et al., 2003; Li et al., 2009a,b; 2010).”
BackgroundThe role of short-chain fatty acids in central nervous system diseases
Dong, Y., & Cui, C. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04471-8 · Cited by 89
“Butyrate is also found to induce the apoptosis of colon cancer cell, possibly by activating caspase, reducing anti-apoptotic gene expression (such as Bcl-2, Bcl-W, Bcl-xL, and Bfl-1) and increasing pro-apoptotic gene expression (such as Fas-L, Fas-R, Fadd, and Tnf-R1) [24].”
BackgroundInfluentialLiu, J., Yang, K., Yang, J., Xiao, W., Le, Y., Yu, F., Gu, L., Lang, S., Tian, Q., Jin, T., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.037 · Cited by 85
“In addition to its glucose-lowering effect, GLP-1 can display favorable actions on several systems such as cardiovascular [10], nervous [11] and bone [12] systems.”
BackgroundXiao-Yun, X., Zhao-Hui, M., Ke, C., Hong-Hui, H., & Yan-Hong, X. (2011) · Medical Science Monitor · doi:10.12659/msm.881383 · Cited by 88
“Previous studies have shown that GLP-1 secreted from the gut is an incretin that has diverse actions, including promotion of propagation and differentiation of pancreatic islet B cells, increased secretion of insulin, inhibition of food and water intake, gastric emptying, and stimulation of neuroendocrine responses ch…”
BackgroundGLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87
“It is also consistent with the protective effect of GLP-1R agonists against pyridoxineinduced peripheral sensory neuropathy [21] and in models of stroke, Parkinson’s disease and Alzheimer’s disease [29,30].”
ResultNeuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model
Li, Y., Liu, W., Li, L., & Hölscher, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.10.002 · Cited by 87
“Also, a drug that is on the market to treat type 2 diabetes, Exenatide (exendin-4), showed a therapeutic effect in preclinical tests (Harkavyi et al., 2008; Kim et al., 2009; Li et al., 2009) and in a pilot clinical trial in PD patients (Aviles-Olmos et al.”
Self-citationJalewa, J., Sharma, M. K., Gengler, S., & Hölscher, C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.02.013 · Cited by 86
“Importantly, previous investigations found that GLP-1 receptor agonists also showed good neuroprotective effects in different animal models of PD (Bertilsson et al., 2008; Harkavyi et al., 2008; Li et al., 2009; Liu et al., 2015a; Zhang et al., 2015) and showed good effects in a pilot study in PD patients (Aviles-Olmo…”
Bayliss, J. A., Lemus, M. B., Santos, V. V., Deo, M., Davies, J. S., Kemp, B. E., Elsworth, J. D., & Andrews, Z. B. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159381 · Cited by 75
“GLP1 also has receptors on SN dopaminergic neurons and prevents neurodegeneration in a mouse model of PD [65, 66].”
BackgroundType 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts
Cullinane, P. W., Pablo‐Fernández, E. D., König, A., Outeiro, T. F., Jaunmuktane, Z., & Warner, T. T. (2022) · Movement Disorders · doi:10.1002/mds.29298 · Cited by 82
“agonists Exenatide • Stimulates subventricular area neurogenesis in rodents(242) and increases TH levels in primary dopaminergic neurons.(243)”
BackgroundThe hormesis principle of neuroplasticity and neuroprotection
Mattson, M. P., & Leak, R. K. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.022 · Cited by 82
Self-citationGLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
Monti, G., Gomes Moreira, D., Richner, M., Mutsaers, H. A. M., Ferreira, N., & Jan, A. (2022) · Cells · doi:10.3390/cells11132023 · Cited by 68
“For instance, in cultures of embryonic cortical neurons, exendin-4 promoted neurite growth and protected against cell death induced by hypoxia and the mitochondrial toxin 6-hydroxydopamine (6OHDA) [63].”
BackgroundErdogdu, Ö., Eriksson, L., Xu, H., Sjöholm, Å., Zhang, Q., & Nyström, T. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0166 · Cited by 75
“GLP1 and its derivates have previously been assigned an anti-apoptotic role in murine HL-1 cardiomyocytes (Ravassa et al. 2011), pancreatic b-cells (Cunha et al. 2009, Kim et al. 2010), and neuronal cells (Li et al. 2009).”
BackgroundAkt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment
Greene, L. A., Levy, O., & Malagelada, C. (2011) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-011-9671-8 · Cited by 79
“GLP-1 receptors appear to be widely expressed in the nervous system and the protective actions of exendin-4 in at least one PD model were dependent on their presence (Li et al., 2009).”
InfluentialJalewa, J., Sharma, M. K., & Hölscher, C. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13736 · Cited by 73
“Further studies also show that Exendin-4 protects dopaminergic neurons (Kim et al. 2009; Li et al. 2009).”
BackgroundTherapeutic effect of berberine on TDP-43-related pathogenesis in FTLD and ALS
Chang, C.-F., Lee, Y., Lee, K., Lin, H., Chen, C., Shen, C.-K. J., & Huang, C.-C. S. (2016) · Journal of Biomedical Science · doi:10.1186/s12929-016-0290-z · Cited by 78
Nizari, S., Basalay, M., Chapman, P., Korte, N., Korsak, A., Christie, I. N., Theparambil, S. M., Davidson, S. M., Reimann, F., Trapp, S., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-021-00873-9 · Cited by 77
“There is evidence that treatment with GLP-1R agonists increases GLP1R expression, increases the level of the neurotrophic factor BDNF, protects the blood–brain barrier through MMP-9 regulation, decreases microglial activation, oxidative stress and the release of apoptotic factors [41, 48, 50, 51, 78, 85].”
BackgroundBatista, A. F., Bodart‐Santos, V., Felice, F. G. D., & Ferreira, S. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0593-6 · Cited by 77
Greig, N. H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., Chiang, Y.-H., Hoffer, B. J., Miller, J., Lahiri, D. K., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.011 · Cited by 70
“[123] Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW,”
Self-citationYang, J.-L., Chen, W.-Y., Chen, Y.-P., Kuo, C.-Y., & Chen, S.-D. (2016) · Theranostics · doi:10.7150/thno.15993 · Cited by 74
“Many studies have revealed that GLP-1[32,44], EX-4 [45-47], and other agonists of GLP-1R [40,48] have a neuroprotective role against neurodegenerative cell death, traumatic brain injury, and ischemic stroke.”
BackgroundInfluentialGLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74
The multi‐faceted role of mitochondria in the pathology of Parkinson’s disease
Trinh, D., Israwi, A. R., Arathoon, L. R., Gleave, J. A., & Nash, J. E. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15154 · Cited by 74
Cui, Q. N., Stein, L. M., Fortin, S. M., & Hayes, M. R. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15683 · Cited by 71
“…effects (Li et al., 2009; McClean et al., 2011; Perry et al., 2002; Sterling et al., 2020b), while reducing β-amyloid plaque accumulation (Li et al., 2009; McClean et al., 2011; Perry et al., 2003), enhancing neuronal progenitor cell differentiation (Hamilton et al., 2011; McClean et…”
BackgroundUnveiling a common mechanism of apoptosis in β-cells and neurons in Friedreich's ataxia
Igoillo‐Esteve, M., Gurgul-Convey, E., Hu, A., Santos, L. R. B., Abdulkarim, B., Chintawar, S., Marselli, L., Marchetti, P., Jonas, J., Eizirik, D. L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu745 · Cited by 75
“Their therapeutic potential is being considered in amyotrophic lateral sclerosis (48), Alzheimer’s (49), Parkinson’s (50) and Huntington’s disease (51) and stroke (52,53).”
BackgroundMaluf, F. C., Feder, D., & Carvalho, A. A. D. S. (2019) · Parkinson s Disease · doi:10.1155/2019/4951379 · Cited by 73
Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases
Chen, S., Chuang, Y., Lin, T., & Yang, J. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175439 · Cited by 73
Faivre, É., Hamilton, A., & Hölscher, C. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.007 · Cited by 73
“Other incretin analogues such as exendin-4 (Li et al., 2009), (Val(8))GLP-1 (Gengler et al.”
BackgroundChen, S., Yu, S.-J., Li, Y., Lecca, D., Glotfelty, E., Kim, H. K., Choi, H.-I., Hoffer, B. J., Greig, N. H., Kim, D. S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-28449-z · Cited by 68
Self-citationTargeting Microglia to Treat Degenerative Eye Diseases
Wang, S. K., & Cepko, C. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843558 · Cited by 72
“However, GLP-1R agonists may additionally possess neuroprotective properties, which have been attributed to their actions on microglia and subsequently astrocytes (101, 103, 104).”
BackgroundLiu, T., Sun, Z., Yang, Z., & Qiao, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114586 · Cited by 73
Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice
Bomba, M., Granzotto, A., Castelli, V., Massetti, N., Silvestri, E., Canzoniero, L. M. T., Cimini, A., & Sensi, S. L. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.009 · Cited by 69
Diminished mTOR signaling: a common mode of action for endocrine longevity factors
Lamming, D. W. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-735 · Cited by 71
“…no aging studies have been conducted with GLP-1 in healthy aged animals, GLP-1 has attracted some excitement as a possible therapy for diseases of neuronal injury, including Alzheimer’s disease, stroke, Huntington’s disease, and Parkinson’s disease (Li et al. 2009, 2010; Martin et al. 2009).”
Ma, J., Shi, M., Zhang, X., Liu, X., Chen, J., Zhang, R., Wang, X., & Zhang, H. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3509 · Cited by 47
“agonists exhibit neurotrophic and neuroprotective properties in certain neurons and neural cells (16,30-34).”
Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease
Saha, P., Kathuria, H., & Pandey, M. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.04.021 · Cited by 71
Exendin-4 Ameliorates Traumatic Brain Injury-Induced Cognitive Impairment in Rats
Eakin, K., Li, Y., Chiang, Y.-H., Hoffer, B. J., Rosenheim, H., Greig, N. H., & Miller, J. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082016 · Cited by 67
“The presence of the GLP-1R was verified, in accord with prior studies [21,36], on both SHSY5Y human neuroblastoma cells and rat primary neurons by RT-RCR; GLP-1R mRNA possessed the expected RT–PCR product size of 190 bp.”
BackgroundMethodResultSelf-citationRepeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
Briyal, S., Gulati, K., & Gulati, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.026 · Cited by 71
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 69
Tsai, T., Sun, C., Su, C.-H., Sung, P., Chua, S. O., Zhen, Y., Leu, S., Chang, H., Yang, J., & Yip, H. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000529 · Cited by 69
“Interestingly, enhancing circulating GLP-1 levels was also found improvement of outcome in nondiabetes acute stroke model [25,57].”
BackgroundResultPandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
“Importantly, these protective effects were not observed in neurons from GLP-1R knockout mice [50].”
BackgroundChen, S., An, F.-M., Yin, L., Liu, A.-R., Yin, D.-K., Yao, W.-B., & Gao, X.-D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.10.038 · Cited by 68
“GLP-1R stimulation improved functional outcomes in well-characterized cellular and animal models of both stroke and Parkinson’s disease (Li et al., 2009).”
Bidirectional metabolic regulation of neurocognitive function
Stranahan, A. M., & Mattson, M. P. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.01.004 · Cited by 62
Self-citationType 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach
Sabari, S. S., Balasubramani, K., Iyer, M., Babu, H. W. S., Venkatesan, D., Gopalakrishnan, A. V., Narayanaswamy, A., Kumar, N. S., & Vellingiri, B. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03359-y · Cited by 68
Elgueta, D., Aymerich, M. S., Contreras, F., Montoya, A., Celorrio, M., Rojo-Bustamante, E., Riquelme, E., González, H., Vásquez, M., Franco, R., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.028 · Cited by 67
“In this regard, these drugs tested in MPTPintoxicated mice prevented the loss of nigrostriatal neurons, decreased neuroinflammation and improved motor impairment (Kim et al., 2009; Li et al., 2009).”
BackgroundPanagaki, T., Michael, M., & Hölscher, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16488-x · Cited by 61
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Mattson, M. P. (2014) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130335 · Cited by 59
“Dopaminergic neurons express GLP-1 receptors and treatment of cultured dopaminergic neurons with GLP-1 or the long-acting GLP-1 analog Exendin-4 protects those neurons from being damaged by 6-hydroxydopamine [138].”
Self-citationOnoviran, O. F., Li, D., Toombs Smith, S., & Raji, M. A. (2019) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622319862691 · Cited by 57
Lv, M., Xue, G., Cheng, H., Meng, P., Lian, X., Hölscher, C., & Li, D. (2021) · Brain and Behavior · doi:10.1002/brb3.2231 · Cited by 58
Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances
Asmar, M., & Holst, J. J. (2010) · Current Opinion in Endocrinology, Diabetes and Obesity · doi:10.1097/med.0b013e3283339051 · Cited by 60
Knippenberg, S., Thau, N., Dengler, R., Brinker, T., & Petri, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036857 · Cited by 61
“While analogues of GLP-1, like exendin 4 or liraglutide, showed neuroprotective potential in models of Alzheimer’s [20] and Parkinson’s disease [19,41], the effect in ALS mice so far has been insufficient.”
BackgroundLi, Y., Liu, W., Li, L., & Hölscher, C. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.11.050 · Cited by 64
“(GLP-1R) that is on the market to treat T2DM, showed therapeutic effects in preclinical tests (Kim et al., 2009; Li et al., 2009).”
BackgroundSelf-citationAcylated but not des‐acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson's disease
Bayliss, J. A., Lemus, M., Santos, V. V., Deo, M., Elsworth, J. D., & Andrews, Z. B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13576 · Cited by 56
“dopamine neurons to prevent neurodegeneration in mouse models of PD (Bertilsson et al. 2008; Li et al. 2009).”
BackgroundFerrari, F., Moretti, A., & Villa, R. F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108277 · Cited by 59
Metadata
- Authors
- Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., Brossi, A., Lahiri, D. K., Mattson, M. P., Hoffer, B. J., Wang, Y., & Greig, N. H.
- Affiliations
- National Institute on Aging (US)
- Medical University of South Carolina (US)
- National Institute on Drug Abuse (US)
- University of North Carolina at Chapel Hill (US)
- Indiana University School of Medicine (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-01-27
- Volume
- 106
- Issue
- 4
- Pages
- 1285-1290
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2633544
- OpenAlex
- W2080785707
- Cited by
- 589
- References
- 45
- Citations by year
- 2026: 18 · 2025: 39 · 2024: 39 · 2023: 24 · 2022: 33 · 2021: 49 · 2020: 41 · 2019: 40 · 2018: 43 · 2017: 34 · 2016: 41 · 2015: 45 · 2014: 34 · 2013: 33 · 2012: 27
- FWCI
- 16.16
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- University of Toronto
- National Institutes of Health
- National Institute on Aging
- National Institute on Drug Abuse
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- GLP-1 receptor, exendin-4, stroke, Parkinson's disease, dopaminergic neurons, cortical neurons, neuroprotection, MPTP mouse model, middle cerebral artery occlusion, 6-hydroxydopamine, hypoxia, oxidative stress, dopamine levels, motor function
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Cells, Cultured, Cerebral Cortex, Disease Models, Animal, Dopamine, Embryo, Mammalian, Gene Expression Regulation, Humans, Mesencephalon, Neurons, Parkinson Disease, Peptides, Venoms, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Hypoxia, Treatment Outcome, Cell Death, Receptors, Glucagon, Cytoprotection, Brain Infarction, Stroke, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.